keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/29786490/gallium-68-psma-11-pet-mr-imaging-in-patients-with-intermediate-or-high-risk-prostate-cancer
#1
Sonya Youngju Park, Claudia Zacharias, Caitlyn Harrison, Richard E Fan, Christian Kunder, Negin Hatami, Frederik Giesel, Pejman Ghanouni, Bruce Daniel, Andreas M Loening, Geoffrey A Sonn, Andrei Iagaru
Purpose To report the results of dual-time-point gallium 68 (68 Ga) prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/magnetic resonance (MR) imaging prior to prostatectomy in patients with intermediate- or high-risk cancer. Materials and Methods Thirty-three men who underwent conventional imaging as clinically indicated and who were scheduled for radical prostatectomy with pelvic lymph node dissection were recruited for this study. A mean dose of 4.1 mCi ± 0.7 (151.7 MBq ± 25...
May 16, 2018: Radiology
https://www.readbyqxmd.com/read/29785515/prostate-specific-antigen-flare-induced-by-223-racl-2-in-patients-with-metastatic-castration-resistant-prostate-cancer
#2
Angelo Castello, H A Macapinlac, E Lopci, E B Santos
PURPOSE: Prostate-specific antigen (PSA) flare is a well-known phenomenon in patients with prostate cancer, but its impact during radium-223 dichloride (223 RaCl2 ) therapy is still unclear. This radioisotope has shown to improve overall survival in metastatic castration-resistant prostate cancer (mCRPC). We sought to evaluate the impact of PSA flare on survival and its relation with metabolic parameters on 18 F-labeled sodium fluoride PET/CT. METHODS: We conducted a retrospective study of 168 patients with mCRPC (median age 69; median PSA 29...
May 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29782606/-68-ga-psma-and-11-c-choline-comparison-using-a-tri-modality-pet-ct-mri-3-0-t-system-with-a-dedicated-shuttle
#3
Omar Alonso, Gerardo Dos Santos, Margarita García Fontes, Henia Balter, Henry Engler
Background: The aim of this study was to prospectively compare the detection rate of 68 Ga-PSMA versus 11 C-Choline in men with prostate cancer with biochemical recurrence and to demonstrate the added value of a tri-modality PET/CT-MRI system. Methods: We analysed 36 patients who underwent both 11 C-Choline PET/CT and 68 Ga-PSMA PET/CT scanning within a time window of 1-2 weeks. Additionally, for the 68 Ga-PSMA scan, we used a PET/CT-MRI (3.0 T) system with a dedicated shuttle, acquiring MRI images of the pelvis...
2018: European journal of hybrid imaging
https://www.readbyqxmd.com/read/29782605/trends-in-oncologic-hybrid-imaging
#4
REVIEW
Andreas G Wibmer, Hedvig Hricak, Gary A Ulaner, Wolfgang Weber
Hybrid imaging plays a central role in the diagnosis and management of a wide range of malignancies at all stages. In this article, we review the most pertinent historical developments, emerging clinical applications of novel radiotracers and imaging technologies, and potential implications for training and practice. This includes an overview of novel tracers for prostate, breast, and neuroendocrine tumors, assessment of tumor heterogeneity, the concept of image-guided 'biologically relevant dosing', and theranostic applications...
2018: European journal of hybrid imaging
https://www.readbyqxmd.com/read/29777523/application-of-cu-64-nodaga-psma-pet-in-prostate-cancer
#5
Sabina Sevcenco, Hans Christoph Klingler, Klaus Eredics, Alexander Friedl, Jenifer Schneeweiss, Peter Knoll, Thomas Kunit, Lukas Lusuardi, Siroos Mirzaei
INTRODUCTION: The high diagnostic potential of 64 Cu-PSMA PET-CT imaging was clinically investigated in prostate cancer patients with recurrent disease and in the primary staging of selected patients with advanced local disease. The aim of our study is to assess the uptake behavior in the clinical setting of 64Copper Prostate-Specific Membrane Antigen (64 Cu PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) in prostate cancer. METHODS: A retrospective study was performed in 23 patients with intermediate, high risk and progressive disease at primary staging of prostate cancer...
May 17, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29769114/-68-ga-psma-pet-ct-for-the-evaluation-of-pulmonary-metastases-and-opacities-in-patients-with-prostate-cancer
#6
Jonathan Damjanovic, Jan-Carlo Janssen, Christian Furth, Gerd Diederichs, Thula Walter, Holger Amthauer, Marcus R Makowski
BACKGROUND: The purpose of this study was to investigate the imaging properties of pulmonary metastases and benign opacities in 68 Ga-PSMA positron emission tomography (PET) in patients with prostate cancer (PC). METHODS: 68 Ga-PSMA-PET/CT scans of 739 PC patients available in our database were evaluated retrospectively for lung metastases and non-solid focal pulmonary opacities. Maximum standardized uptake values (SUVmax ) were assessed by two- and three-dimensional regions of interest (2D/3D ROI)...
May 16, 2018: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/29766246/comparison-of-68-ga-ga-psma-11-pet-ct-with-18-f-naf-pet-ct-in-the-evaluation-of-bone-metastases-in-metastatic-prostate-cancer-patients-prior-to-radionuclide-therapy
#7
Christian Uprimny, Anna Svirydenka, Josef Fritz, Alexander Stephan Kroiss, Bernhard Nilica, Clemens Decristoforo, Roland Haubner, Elisabeth von Guggenberg, Sabine Buxbaum, Wolfgang Horninger, Irene Johanna Virgolini
AIM: The purpose of this study was to investigate the diagnostic performance of 68 Ga-PSMA-11 PET/CT in the evaluation of bone metastases in metastatic prostate cancer (PC) patients scheduled for radionuclide therapy in comparison to [18 F]sodium fluoride (18 F-NaF) PET/CT. METHODS: Sixteen metastatic PC patients with known skeletal metastases, who underwent both 68 Ga-PSMA-11 PET/CT and 18 F-NaF PET/CT for assessment of metastatic burden prior to radionuclide therapy, were analysed retrospectively...
May 16, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29762238/diagnostic-performance-of-18f-fluciclovine-in-detection-of-prostate-cancer-bone-metastases
#8
Albert Chau, Peter Gardiner, Patrick M Colletti, Hossein Jadvar
PURPOSE: 18F-fluciclovine is a synthetic amino acid radiotracer that has recently been approved in Europe and the United States for PET imaging in men with biochemical recurrence (BCR) of prostate cancer after prior definitive treatment. Accurate identification of the sites of disease in patients presenting with BCR of prostate cancer is important in determining the appropriate treatment. Bone is the most frequent site of metastatic disease in patients with prostate cancer. METHODS: We conducted a comprehensive review of the available preclinical and clinical data on the diagnostic performance of 18F-fluciclovine PET/CT in an attempt to draw practical and general conclusions on the utility and limitations of 18F-fluciclovine PET/CT in localization of osseous metastatic disease in prostate cancer...
May 14, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29761524/the-24th-annual-prostate-cancer-foundation-scientific-retreat-report
#9
REVIEW
Andrea K Miyahira, Howard R Soule
INTRODUCTION: The 24th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 5-7, 2017, at the Omni Shoreham Hotel in Washington, DC. METHODS: The PCF Scientific Retreat is a scientific conference that specifically focuses on cutting edge research deemed to have significant promise for accelerating advances in prostate cancer biology and treatment. RESULTS: Themes highlighted at this year's meeting included: (i) new understandings in prostate cancer biology and disease progression; (ii) new mechanisms and treatment targets in advanced prostate cancer; (iii) advances in precision medicine genomics, germline genetics, and selection of targeted therapies; (iv) PSMA-targeted agents for PET imaging and radionuclide therapy; (v) approaches for improving the efficacy of immunotherapy in prostate cancer; (vi) applications of 3D Genomics in prostate cancer research; and (vii) potential applications of artificial intelligence in prostate cancer...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29755660/measuring-glucocorticoid-receptor-expression-in-vivo-with-pet
#10
Charles Truillet, Matthew F L Parker, Loc T Huynh, Junnian Wei, Khaled M Jami, Yung-Hua Wang, Yuqin S Shen, Renuka Sriram, David M Wilson, John Kurhanewicz, Michael J Evans
The glucocorticoid receptor (GR) is an emerging drug target for several common and deadly solid tumors like breast and prostate cancer, and clinical trials studying the antitumor effects of GR antagonists are beginning. Since GR expression can be variable in tumor cells, and virtually all normal mammalian tissues express some GR, we hypothesized that an imaging tool capable of detecting GR positive tumors and/or measuring GR occupancy by drug in tumor and normal tissues could improve the precision application of anti-GR therapies in the clinic...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29752513/oligorecurrent-prostate-cancer-limited-to-lymph-nodes-getting-our-ducks-in-a-row
#11
Andrei Fodor, Andrea Lancia, Francesco Ceci, Maria Picchio, Morten Hoyer, Barbara Alicja Jereczek-Fossa, Piet Ost, Paolo Castellucci, Elena Incerti, Nadia Di Muzio, Gianluca Ingrosso
PURPOSE: Oligorecurrent prostate cancer with exclusive nodal involvement represents a common state of disease, amenable to local therapy. New radio-labeled tracers have enriched the possibility of cancer detection and treatment. In this review, we aim to illustrate the main nuclear medicine diagnostic options and the role of radiotherapy in this setting of patients. METHODS: We performed a PubMed search referring to the PRISMA guidelines to analyze the performance of PSMA- and choline-PET in detecting oligorecurrence limited to lymph nodes, and to review the main studies supporting either ablative stereotactic body radiotherapy or regional lymph node irradiation in this clinical setting...
May 11, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29752180/-177-lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-lupsma-trial-a-single-centre-single-arm-phase-2-study
#12
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments...
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29751842/psma-pet-based-radiotherapy-a-review-of-initial-experiences-survey-on-current-practice-and-future-perspectives
#13
REVIEW
Sebastian Zschaeck, Fabian Lohaus, Marcus Beck, Gregor Habl, Stephanie Kroeze, Constantinos Zamboglou, Stefan Alexander Koerber, Jürgen Debus, Tobias Hölscher, Peter Wust, Ute Ganswindt, Alexander D J Baur, Klaus Zöphel, Nikola Cihoric, Matthias Guckenberger, Stephanie E Combs, Anca Ligia Grosu, Pirus Ghadjar, Claus Belka
68 Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy. Owed to the novelty of the PSMA-targeting tracers, clinical evidence on the value of PSMA-PET is moderate but rapidly increasing. State of the art imaging is pivotal for radiotherapy treatment planning as it may affect dose prescription, target delineation and use of concomitant therapy...
May 11, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29748236/modeling-and-predicting-tumor-response-in-radioligand-therapy
#14
Peter Kletting, Anne Thieme, Nina Eberhardt, Andreas Rinscheid, Calogero D'Alessandria, Jakob Allmann, Hans-Jürgen Wester, Robert Tauber, Ambros J Beer, Gerhard Glatting, Matthias Eiber
The aim of this work was to develop a theranostic method that allows predicting PSMA-positive tumor volume after radioligand therapy (RLT) based on a pre-therapeutic PET/CT measurement and physiologically based pharmacokinetic/dynamic (PBPK/PD) modeling at the example of RLT using 177 Lu-labeled PSMA for imaging and therapy (PSMA I&T). Methods: A recently developed PBPK model for 177 Lu PSMA I&T RLT was extended to account for tumor (exponential) growth and reduction due to irradiation (linear quadratic model)...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29747035/microscale-radiosynthesis-preclinical-imaging-and-dosimetry-study-of-18-f-ambf-3-tate-a-potential-pet-tracer-for-clinical-imaging-of-somatostatin-receptors
#15
Ksenia Lisova, Maxim Sergeev, Susan Evans-Axelsson, Andreea D Stuparu, Seval Beykan, Jeffrey Collins, Jason Jones, Michael Lassmann, Ken Herrmann, David Perrin, Jason T Lee, Roger Slavik, R Michael van Dam
BACKGROUND: Peptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging...
April 20, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29745629/psa-levels-as-a-predictor-of-68ga-psma-pet-ct-positivity-in-patients-with-prostate-cancer
#16
Cigdem Soydal, Yuksel Urun, Evren Suer, Demet Nak, Elgin Ozkan, Ozlem N Kucuk
BACKGROUND: The aim of this study is to evaluate predictive factors of 68Gallium (68Ga) Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) positivity. METHODS: Relationships between serum Prostate Specific Antigen (PSA), Lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) levels, Gleason Score (GS) and positivity of 68Ga PSMA PET in patients who underwent 68Ga PSMA PET/CT for restaging for PCa were evaluated retrospectively...
May 10, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29743623/in-vivo-molecular-imaging-of-glutamate-carboxypeptidase-ii-expression-in-re-endothelialisation-after-percutaneous-balloon-denudation-in-a-rat-model
#17
Heike Endepols, Felix M Mottaghy, Sakine Simsekyilmaz, Jan Bucerius, Felix Vogt, Oliver Winz, Raphael Richarz, Philipp Krapf, Bernd Neumaier, Boris D Zlatopolskiy, Agnieszka Morgenroth
The short- and long-term success of intravascular stents depends on a proper re-endothelialisation after the intervention-induced endothelial denudation. The aim of this study was to evaluate the potential of in vivo molecular imaging of glutamate carboxypeptidase II (GCPII; identical with prostate-specific membrane antigen PSMA) expression as a marker of re-endothelialisation. Fifteen Sprague Dawley rats underwent unilateral balloon angioplasty of the common carotid artery (CCA). Positron emission tomography (PET) using the GCPII-targeting tracer [18 F]DCFPyL was performed after 5-21 days (scan 60-120 min post injection)...
May 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29742609/incidental-metastatic-melanoma-identified-on-68ga-prostate-specific-membrane-antigen-pet-ct-for-metastatic-prostate-cancer
#18
Hayden A Snow, Michael S Hofman, Catherine A Mitchell, David E Gyorki, Myles J F Smith
A 78-year-old man with a history of surgically treated prostate cancer and melanoma underwent Ga-prostate-specific membrane antigen (PSMA) PET/CT for biochemical recurrence of his prostate cancer. This revealed locoregionally recurrent prostate cancer and a separate PSMA-avid nodule in his left arm. Subsequent F-FDG PET/CT and excision confirmed this to be an in-transit melanoma metastasis. Prostate-specific membrane antigen PET/CT has become a widely used and valuable tool in the assessment of prostate cancer, particularly biochemically recurrent...
April 30, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29742600/incidental-detection-of-meningioma-by-18f-fmau-pet-ct-in-a-patient-with-suspected-prostate-cancer
#19
Bino Varghese, Erik Velez, Bhushan Desai, Hossein Jadvar
We report on an incidental detection of a meningioma on [F]-2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) PET/CT scan that was performed during a prospective investigation of F-FMAU PET/CT for targeted biopsy of potential sites of tumor in men with suspected prostate cancer based on elevated prostate-specific antigen level. Neither prostate multiparamteric MRI nor F-FMAU PET/CT localized small volume Gleason 3 + 3 tumor deposits. However, an incidental focal high accumulation of F-FMAU was observed in high right parietal lobe that displayed characteristics of a meningioma on a subsequent brain MRI...
May 7, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29736561/the-utility-of-18-f-dasa-23-for-molecular-imaging-of-prostate-cancer-with-positron-emission-tomography
#20
Corinne Beinat, Tom Haywood, Yun-Sheng Chen, Chirag B Patel, Israt S Alam, Surya Murty, Sanjiv Sam Gambhir
PURPOSE: There is a strong, unmet need for superior positron emission tomography (PET) imaging agents that are able to measure biochemical processes specific to prostate cancer. Pyruvate kinase M2 (PKM2) catalyzes the concluding step in glycolysis and is a key regulator of tumor growth and metabolism. Elevation of PKM2 expression was detected in Gleason 8-10 tumors compared to Gleason 6-7 carcinomas, indicating that PKM2 may potentially be a marker of aggressive prostate cancer. We have recently reported the development of a PKM2-specific radiopharmaceutical [18 F]DASA-23 and herein describe its evaluation in cell culture and preclinical models of prostate cancer...
May 7, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"